Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,662 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Recruiting Phase 3 Interventional

PAH Exercise Study

NCT06941441
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Exercise Therapy
Interventions
Home exercise program
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00454194
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed disodium, sorafenib tosylate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
207
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 3 Interventional

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT02125253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg, Placebo Nasal Spray
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

NCT00867139
View directory record Official record
Conditions
Influenza
Interventions
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 20, 2026, 10:13 PM EDT
Terminated Not applicable Interventional Results available

AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19

NCT04649775
View directory record Official record
Conditions
Corona Virus Infection, Respiratory Rate, Hypoxia, Covid19
Interventions
AirFLO2
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 20, 2026, 10:13 PM EDT
Completed No phase listed Observational

Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only

NCT01536457
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Children's Center for Digestive Health Care
Other
Eligibility
4 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

NCT00080457
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
sitaxsentan sodium
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Oct 20, 2026, 10:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479
View directory record Official record
Conditions
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
Interventions
[212Pb]Pb-MP0712, [203Pb]Pb-MP0712
Drug · Other
Lead sponsor
Molecular Partners AG
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Completed No phase listed Observational

Post-extubation Assessment of Laryngeal Symptoms and Severity

NCT03726086
View directory record Official record
Conditions
Intubation, Intratracheal, Critical Illness, Mechanical Ventilation Complication, Complication of Ventilation Therapy
Interventions
laryngoscopy
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 20, 2026, 10:13 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea

NCT02494102
View directory record Official record
Conditions
Obstructive Sleep Apnea, Delayed Emergence From Anesthesia
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 20, 2026, 10:13 PM EDT
Terminated Phase 1 Interventional

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT04524195
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
[18F]F-AraG Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Therapeutic Intervention Supporting Development From NICU to 6 Months for Infants Post Hypoxic-Ischemic Encephalopathy

NCT05130528
View directory record Official record
Conditions
Cerebral Palsy, Hypoxic-Ischemic Encephalopathy
Interventions
Sensorimotor Intervention
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
Up to 6 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

A Study of LAM-002A for the Prevention of Progression of COVID-19

NCT04446377
View directory record Official record
Conditions
COVID-19 Disease
Interventions
Apilimod Dimesylate Capsule, Placebo
Drug · Other
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT01597375
View directory record Official record
Conditions
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Interventions
Placebo Oral Tablet, Prasugrel Oral Tablet
Drug
Lead sponsor
Elliot Israel, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 20, 2026, 10:13 PM EDT
Completed No phase listed Observational

Asthma in Pregnancy

NCT05047419
View directory record Official record
Conditions
Asthma, Pregnancy
Interventions
Not listed
Lead sponsor
Linnea Polgreen
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

NCT03240575
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT00979212
View directory record Official record
Conditions
Lung Cancer
Interventions
panitumumab, carboplatin, paclitaxel, surgery
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
31
States / cities
Carmichael, California • Sacramento, California • Colorado Springs, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

NCT01457781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
16 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 20, 2026, 10:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Completed No phase listed Observational

Linking Former Inmates to Primary Care

NCT01863290
View directory record Official record
Conditions
Hypertension, Substance Abuse, Asthma, Depression
Interventions
Primary care redesign
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Martinez, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 20, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07761910
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
Interventions
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
Diagnostic Test · Device · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Completed No phase listed Observational

Cardiotoxicity of Radiation Therapy (CTRT)

NCT02769299
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Mediastinal Lymphomas
Interventions
Radiation Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab in combination with Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 20, 2026, 10:13 PM EDT